Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

ImmunityBio Inc. (IBRX)

NASDAQ: IBRX · Biological Products, (No Diagnostic Substances) · San Diego, CA

Our rating: Cautious

Cautious reaffirmed at $6.75, moderate conviction, November 10, 2026.

Breaks if: The Cautious view is wrong if ImmunityBio reports an annualized revenue run rate above $350M within four quarters from now while simultaneously narrowing its quarterly net cash burn below $60M — both thresholds must clear together, since either alone would not demonstrate that the cost base is genuinely absorbing the revenue ramp. If that combination appears in the filings, the path to eventual self-funding becomes visible enough to revisit the rating upward.

Key figures

Market value$6.4B
Revenue, last 12 months$183M
Net income, last 12 months−$1.1B
Free cash flow, last 12 months−$297M
Price to earningsn/a
Free cash flow yield−4.6%
Dividend yield0.0%
Operating margin−150.2%
Return on equityn/a
Beta to the S&P 5001.52
Volatility, annualized97.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$49M52.3%$-0.18−$78M
June 30, 2026$51M93.9%$-0.22−$70M
March 31, 2026$44M167.6%$-0.62−$77M
December 31, 2025$38M407.0%$-0.06−$71M
September 30, 2025$32M425.1%$-0.07−$70M
June 30, 2025$26M2423.9%$-0.10−$81M
March 31, 2025$17M41192.5%$-0.15−$87M
December 31, 2024$8M5333.1%$-0.09−$87M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

38 ledger entries and 51 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.